News Releases
January 11, 2021
Synlogic Outlines Upcoming Clinical Milestones
December 14, 2020
Synlogic Announces Advancement of SYNB1891 to Combination Arm Dosing with PD-L1 Checkpoint Inhibitor in the on-going Phase 1 Study for the Treatment of Solid Tumors and Lymphoma
December 9, 2020
Synlogic Appoints Michael Heffernan to its Board of Directors
December 7, 2020
Synlogic Presents SYNB8802 for Enteric Hyperoxaluria at the American Institute of Chemical Engineers Conference on Microbiome Engineering
November 18, 2020
Synlogic to Present at Upcoming Virtual Banking Conference
November 5, 2020
Synlogic Reports Third Quarter 2020 Financial Results and Provides Business Update
November 4, 2020
Synlogic Initiates Phase 1 Study of SYNB8802 for the Treatment of Enteric Hyperoxaluria
October 22, 2020
Synlogic Presents Preclinical Data on SYNB8802 for Enteric Hyperoxaluria at American Society of Nephrology (ASN) Kidney Week 2020
September 14, 2020
Synlogic Appoints David Hava, Ph.D., as Chief Scientific Officer
September 8, 2020
Synlogic to Present at Upcoming Virtual Banking Conferences
August 6, 2020
Synlogic Reports Second Quarter 2020 Financial Results and Provides Business Update
Displaying 1 - 12 of 124